ALTERATION OF THIOREDOXIN REDUCTASE 1 LEVELS IN ELUCIDATING CANCER ETIOLOGY

被引：11

作者：

Yoo, Min-Hyuk ^{[1
]}

Carlson, Bradley A. ^{[1
]}

Tsuji, Petra ^{[1
,2
,5
]}

Irons, Robert ^{[1
]}

Gladyshev, Vadim N. ^{[3
,4
]}

Hatfield, Dolph L. ^{[1
]}

机构：

[1] NCI, Mol Biol Selenium Sect, Lab Canc Prevent, Ctr Canc Res,NIH, Bethesda, MD 20892 USA

[2] NCI, Nutr Sci Res Grp, Canc Prevent Div, NIH, Bethesda, MD 20892 USA

[3] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA

[4] Harvard Univ, Sch Med, Boston, MA USA

[5] NCI, Canc Prevent Fellowship Program, NIH, Bethesda, MD 20892 USA

来源：

METHODS IN ENZYMOLOGY, VOL 474: THIOL REDOX TRANSITIONS IN CELL SIGNALING, PT B: CELLULAR LOCALIZATION AND SIGNALING | 2010年 / 474卷

关键词：

SELENIUM; SELENOCYSTEINE; SELENOPROTEINS; CELLS; THIOREDOXIN-REDUCTASE-1; TRANSCRIPTION; EXPRESSION; PREVENTION; PHENOTYPE; SYSTEM;

D O I：

10.1016/S0076-6879(10)74015-5

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Thioredoxin reductase 1 (TR1) is a major antioxidant and redox regulator in mammalian cells and appears to function as a double-edged sword in that it has roles in preventing and promoting/sustaining cancer. TR1 is overexpressed in many cancer cells and targeting its removal often leads to a reversal in numerous malignant characteristics which has marked this selenoenzyme as a prime target for cancer therapy. Since alterations in TR1 activity may lead to a better understanding of the etiology of cancer and new avenues for providing better therapeutic procedures, we have described herein techniques for removing and reexpressing TR1 employing RNAi technology and for assessing the catalytic activity of this enzyme.

引用

页码：255 / 275

页数：21

共 49 条

[1] The thioredoxin system in cancer
Arner, Elias S. J.
Holmgren, Arne
[J]. SEMINARS IN CANCER BIOLOGY, 2006, 16 (06) : 420 - 426
[2] Focus on mammalian thioredoxin reductases - Important selenoproteins with versatile functions
Arner, Elias S. J.
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2009, 1790 (06): : 495 - 526
[3] Physiological functions of thioredoxin and thioredoxin reductase
Arnér, ESJ
Holmgren, A
[J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (20): : 6102 - 6109
[4] Biaglow JE, 2005, CANCER BIOL THER, V4, P6
[5] Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention
Chew, Eng-Hui
Nagle, Amrita A.
Zhang, Yaochun
Scarmagnani, Silvia
Palaniappan, Puvithira
Bradshaw, Tracey D.
Holmgren, Arne
Westwell, Andrew D.
[J]. FREE RADICAL BIOLOGY AND MEDICINE, 2010, 48 (01) : 98 - 111
[6] Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model
Diwadkar-Navsariwala, Veda
Prins, Gail S.
Swanson, Steven M.
Birch, Lynn A.
Ray, Vera H.
Hedayat, Samad
Lantvit, Daniel L.
Diamond, Alan M.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (21) : 8179 - 8184
[7] High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy
Eriksson, Sofl E.
Prast-Nielsen, Stefanie
Flaberg, Emilie
Szekely, Laszlo
Arner, Elias S. J.
[J]. FREE RADICAL BIOLOGY AND MEDICINE, 2009, 47 (11) : 1661 - 1671
[8] Thioredoxin and protein kinases in redox signaling
Fujino, Go
Noguchi, Takuya
Takeda, Kohsuke
Ichijo, Hidenori
[J]. SEMINARS IN CANCER BIOLOGY, 2006, 16 (06) : 427 - 435
[9] Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase
Gandin, Valentina
Fernandes, Aristi Potamitou
Rigobello, Maria Pia
Dani, Barbara
Sorrentino, Francesca
Tisato, Francesco
Bjornstedt, Mikael
Bindoli, Alberto
Sturaro, Alberto
Rella, Rocco
Marzano, Cristina
[J]. BIOCHEMICAL PHARMACOLOGY, 2010, 79 (02) : 90 - 101
[10] Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene
Gladyshev, VN
Jeang, KT
Stadtman, TC
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (12) : 6146 - 6151

← 1 2 3 4 5 →